Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 Trial A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease
Latest Information Update: 02 Apr 2025
At a glance
- Drugs Zotarolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms FAME 3
Most Recent Events
- 28 Mar 2025 Planned End Date changed from 1 Dec 2024 to 1 Apr 2025.
- 12 Aug 2023 Results of 3years follow-up of Frame-3 trial published in the Circulation.
- 02 Apr 2022 Primary endpoint (To compare EQ-5D summary index at 12 months) has not been met according to the results published in the Circulation